Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31152
Title: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: BMC Psychiatry.2017 07;(17)1:250
Abstract: A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for drug therapy guidance.
PMID: 28705252
URI: https://hdl.handle.net/20.500.12530/31152
Rights: openAccess
Appears in Collections:Hospitales > H. U. Infanta Leonor > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5513031.pdf734 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.